Epitalon vs Pinealon: A Research-Use Comparison of Two Khavinson Bioregulator Peptides
Two short-peptide bioregulators from the same St. Petersburg lineage, studied in different models. Telomere biology meets neuronal oxidative stress, all of it preclinical.
Epitalon, the tetrapeptide AEDG, is studied mainly in telomere and pineal-aging models. Pinealon, the tripeptide EDR, is investigated for neuronal antioxidant and gene-expression endpoints. Both are Khavinson-class short-peptide bioregulators supplied for in vitro and laboratory research use only, never for human use.
Two peptides, one laboratory bench in St. Petersburg, and a shared scientific pedigree that is itself the most interesting fact about them. Epitalon and Pinealon are among the best-known short-peptide bioregulators associated with the work of Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology. Both are synthetic, sequence-defined peptides studied strictly in vitro and in animal models. What follows contains no dose, protocol, or therapeutic claim — these compounds are supplied for laboratory research use only (RUO).
What are Epitalon and Pinealon?
Epitalon (also written Epithalon, or described as Epithalamin-derived) is a tetrapeptide, Ala-Glu-Asp-Gly (AEDG), modelled on the pineal extract epithalamin. In the published literature it is most associated with pineal/circadian and telomere-biology research models. Pinealon is a tripeptide, Glu-Asp-Arg (EDR), belonging to the “cytogen” class of short peptide bioregulators. Reported preclinical work centres on neuronal viability, oxidative balance, and gene-expression endpoints rather than telomere length. The family resemblance is real, but the two are not interchangeable: they are different molecules investigated against different questions.
How do their structures and specifications differ?
The most concrete difference is chemistry. Epitalon is a four-residue peptide and Pinealon is a three-residue peptide, with distinct sequences, CAS numbers, and molecular formulas. Where the two converge is the shelf: both are offered by Condor Research at matched purity and format, so they can be compared on like terms in the lab rather than confounded by handling differences.
| Attribute | Epitalon | Pinealon |
|---|---|---|
| Peptide class | Pineal tetrapeptide bioregulator (AEDG) | Cytogen tripeptide bioregulator (EDR) |
| Sequence | Ala-Glu-Asp-Gly | Glu-Asp-Arg |
| Molecular formula | C14H22N4O9 | C15H26N6O8 |
| CAS number | 307297-39-8 | 175175-23-2 |
| Primary research focus (preclinical) | Telomerase/telomere biology; pineal & circadian aging models | Neuronal viability, antioxidant/ROS defense, gene expression |
| Mechanism investigated | Telomerase induction in cultured human fibroblasts; melatonin/circadian modulation in rodents | ROS suppression and apoptosis reduction in neuronal cultures; epigenetic/gene-expression regulation |
| Vial format | 10 mg/vial lyophilized powder | 10 mg/vial lyophilized powder |
| Capsule format | 60 HPMC caps, 10 mg each | 60 HPMC caps, 10 mg each |
| Purity | ≥99% (HPLC) | ≥99% (HPLC) |
| Characterization | HPLC purity; COA available per lot | HPLC purity; COA available per lot |
| Status | Research Use Only — not for human or veterinary use | |
Side-by-side specifications. The chemistry diverges; the format, purity grade, and documentation are matched by design.
What mechanisms have been studied for Epitalon?
The most cited Epitalon study reported that adding the AEDG peptide to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, telomerase enzymatic activity, and telomere elongation in vitro.1 That single result — telomerase switched on in a somatic cell line that should not express it — is what made the peptide famous. Broader review and in vivo work describe Epitalon and the related pineal preparation epithalamin influencing circadian melatonin rhythms and aging biomarkers in rodents and other species.2 A rodent lifespan study in SHR mice reported reduced chromosome aberrations and altered tumour patterns without a change in mean lifespan in that particular model3 — a useful reminder that results are model-specific, and that a striking in vitro finding need not translate into the crude endpoint of how long an animal lives.
1 residue separates the two peptides in length — a tetrapeptide versus a tripeptide — yet that difference tracks with two largely non-overlapping research literatures.
What mechanisms have been studied for Pinealon?
Pinealon (EDR) research is concentrated in neuronal and oxidative-stress models. In cultured cerebellar granule cells and PC12 cells, Pinealon produced dose-dependent suppression of reactive oxygen species and reduced necrotic cell death.5 An in vivo study reported that administering Pinealon to pregnant rats under a methionine-induced hyperhomocysteinemia model was associated with improved offspring spatial learning and more oxidative-stress-resistant cerebellar neurons.8 Mechanistic reviews place EDR among short peptides proposed to act as epigenetic/gene-expression regulators relevant to neurodegeneration models,6 and a comparative Alzheimer’s mouse-model study found EDR and the related peptide KED reduced amyloid-associated dendritic-spine loss.7 The throughline is neuronal resilience under stress rather than the chromosome-end biology that defines the Epitalon record.
Researchers should treat telomerase activation, neuroprotection, and aging-biomarker effects as hypotheses supported by in vitro and animal data, not settled outcomes.
How strong is the evidence, really?
This is the most important honesty check for both peptides, and it cuts in the same direction for each. The mechanistic evidence for Epitalon and Pinealon is overwhelmingly preclinical — cell culture and rodent studies, the majority from a single research lineage. That concentration matters: independent replication across laboratories is the ordinary test a finding must pass, and much of this body of work has not yet been put through it. There are some long-term human observational reports for the pineal preparation epithalamin and thymalin describing reduced mortality in elderly cohorts,4 but these are older and not equivalent to modern randomised controlled trials, and they concern the polypeptide preparations rather than the isolated synthetic peptides as sold. For the isolated synthetic Epitalon (AEDG) and Pinealon (EDR) specifically, there are no completed, well-powered human efficacy trials establishing the proposed mechanisms. Telomerase activation, neuroprotection, and aging-biomarker effects belong in the column marked hypothesis, not the column marked established.
Which is appropriate for a given research program?
Choice depends entirely on the experimental question, not on any consumer benefit. A study designed around telomere length, telomerase assays, or pineal/circadian endpoints aligns with the published Epitalon literature. A study on neuronal oxidative stress, apoptosis markers, mitochondrial endpoints, or peptide-driven gene expression aligns with the Pinealon literature. Because both are offered at matched 10 mg/vial and 60-capsule formats with ≥99% HPLC purity and per-lot COAs, they can be benchmarked side by side under identical handling. Vials are handled and reconstituted according to standard laboratory practice for lyophilised reference peptides.
Both Epitalon and Pinealon are supplied strictly for research use only — no human or veterinary administration, dosing, or therapeutic interpretation is supported or intended. Each lot ships with a certificate of analysis documenting ≥99% HPLC purity, so the comparison above can be carried out on material of known, verifiable identity.
- Epitalon (AEDG, C14H22N4O9, CAS 307297-39-8) is a four-residue pineal tetrapeptide; Pinealon (EDR, C15H26N6O8, CAS 175175-23-2) is a three-residue cytogen tripeptide.
- Epitalon's literature centres on telomerase induction, telomere biology, and pineal/circadian aging models; Pinealon's centres on neuronal viability, ROS suppression, and gene expression.
- The mechanistic case for both is overwhelmingly preclinical and traces largely to a single research lineage (Khavinson and colleagues), with no well-powered modern human trials of the isolated synthetic peptides.
- Both are offered at matched specifications: 10 mg/vial lyophilised powder and 60 HPMC capsules at 10 mg each, all at ≥99% HPLC purity with per-lot COAs.
- Selection should follow the experimental endpoint, not any consumer benefit; both remain strictly Research Use Only.
Epitalon vs Pinealon: which is better for research?
Neither is universally better — they serve different research questions. Epitalon (AEDG tetrapeptide) is studied in telomere/telomerase and pineal-aging models; Pinealon (EDR tripeptide) is studied in neuronal antioxidant, apoptosis, and gene-expression models. Selection should follow your experimental endpoint. Both are research-use-only and have only preclinical mechanistic support.
What is the structural difference between Epitalon and Pinealon?
Epitalon is a four-amino-acid peptide (Ala-Glu-Asp-Gly, AEDG; C14H22N4O9; CAS 307297-39-8). Pinealon is a three-amino-acid peptide (Glu-Asp-Arg, EDR; C15H26N6O8; CAS 175175-23-2). They are distinct molecules from the same Khavinson short-peptide bioregulator family.
Is there human clinical evidence for either peptide?
No robust modern randomized controlled trials exist for the isolated synthetic Epitalon or Pinealon. Most mechanistic data is in vitro and in rodents. Some older observational human data exists for the related pineal preparation epithalamin, but it is not equivalent to controlled trials of the synthetic peptides as supplied.
Are Epitalon and Pinealon supplied for human use?
No. Both are sold strictly as Research Use Only (RUO) reference compounds for in vitro and laboratory research. They are not drugs, supplements, or for human or veterinary consumption, and no dosing or administration guidance is provided.
What formats and purity does Condor Research offer?
Both peptides are available as 10 mg/vial lyophilized powder and as 60-capsule formats (10 mg per HPMC capsule), each at ≥99% HPLC purity with a certificate of analysis available per lot, enabling like-for-like comparison in research settings.
Do Epitalon and Pinealon work by the same mechanism?
The investigated mechanisms differ. Epitalon's most cited preclinical finding is telomerase induction and telomere elongation in cultured human fibroblasts plus circadian/melatonin effects in animals. Pinealon's preclinical literature centers on reactive-oxygen-species suppression, reduced neuronal cell death, and gene-expression regulation.